Impact of Exercise Training in Combination with Dapagliflozin on Physical Function in Adults with Type 2 Diabetes Mellitus: Study Protocol for the Dapagliflozin, Exercise Training and PhysicAl Function (DETA) Randomised Controlled Trial

Overview

Journal BMJ Open

Specialty General Medicine

Date 2024 Nov 26

PMID 39592159

Authors

Jack A Sargeant

Ehtasham Ahmad

Emily James

Luke Baker

Joanna M Bilak

Nicole A Coull

Gaurav Singh Gulsin

James A King

Kamlesh Khunti

Emma Redman

Alex Rowlands

Emma Watson

Joanne V Wormleighton

Gerry P McCann

Thomas Yates

Melanie J Davies

Affiliations

Soon will be listed here.

Abstract

Introduction: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are associated with weight loss, diverse cardiorenal benefits and improved glycaemic control. However, the effects of SGLT2i on physical function and fitness are uncertain. The Dapagliflozin, Exercise Training and physicAl function trial investigates whether the SGLT2i dapagliflozin, alone or in combination with structured exercise training, improves physical function compared with diet-induced weight loss in adults with type 2 diabetes mellitus (T2DM), overweight/obesity and impaired physical function.

Methods And Analysis: This single-centre randomised controlled trial will assign 1:1:1, 135 adults with T2DM and low physical function to receive one of three treatments: (1) dapagliflozin (10 mg once-daily) alone, (2) dapagliflozin (10 mg once-daily) plus structured exercise training or (3) diet control (where participants are supported to achieve 3% weight loss, equivalent to estimated weight loss with dapagliflozin treatment). Primary and secondary outcomes will be assessed at baseline, 12 and 24 weeks. The primary outcome is the difference in physical function, assessed using the modified Physical Performance Test, between the treatment groups and diet control at 24 weeks. Secondary outcomes include MRI-measured cardiac structure and function, maximal aerobic capacity, resting metabolic rate, device-measured physical activity and sleep, body composition, haemoglobin A1c and cardiovascular risk markers.

Ethics And Dissemination: The Heath Research Authority (HRA) and the Medicines and Healthcare Products Regulatory Authority (MHRA) Research Ethics Committee have approved the study. The findings of the study will be published in peer-reviewed journals.

Trial Registration Number: ISRCTN11459997.

Eudract Number: 2019-004586-41.

References

Ahmad S, Harris T, Limb E, Kerry S, Victor C, Ekelund U . Evaluation of reliability and validity of the General Practice Physical Activity Questionnaire (GPPAQ) in 60-74 year old primary care patients. BMC Fam Pract. 2015; 16:113. PMC: 4557746. DOI: 10.1186/s12875-015-0324-8. View

Ahmad E, Arsenyadis F, Almaqhawi A, Barker M, Jobanputra R, Sargeant J . Impact of novel glucose-lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta-analysis of randomised placebo-controlled trials. Diabet Med. 2023; 40(6):e15083. DOI: 10.1111/dme.15083. View

Gulsin G, Brady E, Swarbrick D, Athithan L, Henson J, Baldry E . Rationale, design and study protocol of the randomised controlled trial: Diabetes Interventional Assessment of Slimming or Training tO Lessen Inconspicuous Cardiovascular Dysfunction (the DIASTOLIC study). BMJ Open. 2019; 9(3):e023207. PMC: 6475184. DOI: 10.1136/bmjopen-2018-023207. View

England C, Andrews R . James Lind Alliance research priorities: should diet and exercise be used as an alternative to drugs for the management of type 2 diabetes or alongside them?. Diabet Med. 2019; 37(4):564-572. DOI: 10.1111/dme.14217. View

Eglseer D, Traxler M, Embacher S, Reiter L, Schoufour J, Weijs P . Nutrition and Exercise Interventions to Improve Body Composition for Persons with Overweight or Obesity Near Retirement Age: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Adv Nutr. 2023; 14(3):516-538. PMC: 10201832. DOI: 10.1016/j.advnut.2023.04.001. View

Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge M, Albu J . Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985). 2004; 97(6):2333-8. DOI: 10.1152/japplphysiol.00744.2004. View

Villareal D, Chode S, Parimi N, Sinacore D, Hilton T, Armamento-Villareal R . Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med. 2011; 364(13):1218-29. PMC: 3114602. DOI: 10.1056/NEJMoa1008234. View

Butt J, Jhund P, Belohlavek J, de Boer R, Chiang C, Desai A . Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation. 2022; 146(16):1210-1224. PMC: 9815819. DOI: 10.1161/CIRCULATIONAHA.122.061754. View

Eckstein M, Williams D, ONeil L, Hayes J, Stephens J, Bracken R . Physical exercise and non-insulin glucose-lowering therapies in the management of Type 2 diabetes mellitus: a clinical review. Diabet Med. 2018; 36(3):349-358. DOI: 10.1111/dme.13865. View

10.

Malik M, Butt J, Strange J, Falkentoft A, Jensen J, Andersson C . Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study. Lancet Healthy Longev. 2023; 4(10):e552-e560. DOI: 10.1016/S2666-7568(23)00164-2. View

11.

Reuben D, Siu A, Kimpau S . The predictive validity of self-report and performance-based measures of function and health. J Gerontol. 1992; 47(4):M106-10. DOI: 10.1093/geronj/47.4.m106. View

12.

Roberts H, Denison H, Martin H, Patel H, Syddall H, Cooper C . A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011; 40(4):423-9. DOI: 10.1093/ageing/afr051. View

13.

Lopez P, Taaffe D, Galvao D, Newton R, Nonemacher E, Wendt V . Resistance training effectiveness on body composition and body weight outcomes in individuals with overweight and obesity across the lifespan: A systematic review and meta-analysis. Obes Rev. 2022; 23(5):e13428. PMC: 9285060. DOI: 10.1111/obr.13428. View

14.

Park S, Goodpaster B, Lee J, Kuller L, Boudreau R, de Rekeneire N . Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care. 2009; 32(11):1993-7. PMC: 2768193. DOI: 10.2337/dc09-0264. View

15.

Malmstrom T, Miller D, Simonsick E, Ferrucci L, Morley J . SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016; 7(1):28-36. PMC: 4799853. DOI: 10.1002/jcsm.12048. View

16.

Bouchi R, Sonoda N, Itoh J, Ono Y, Fukuda T, Takeuchi T . Effects of intensive exercise combined with dapagliflozin on body composition in patients with type 2 diabetes: a randomized controlled trial. Endocr J. 2021; 68(3):329-343. DOI: 10.1507/endocrj.EJ20-0599. View

17.

Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S . Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015; 38(3):365-72. DOI: 10.2337/dc14-0666. View

18.

Gulsin G, Swarbrick D, Hunt W, Levelt E, Graham-Brown M, Parke K . Relation of Aortic Stiffness to Left Ventricular Remodeling in Younger Adults With Type 2 Diabetes. Diabetes. 2018; 67(7):1395-1400. DOI: 10.2337/db18-0112. View

19.

Waddell T, Bagur A, Cunha D, Thomaides-Brears H, Banerjee R, Cuthbertson D . Greater ectopic fat deposition and liver fibroinflammation and lower skeletal muscle mass in people with type 2 diabetes. Obesity (Silver Spring). 2022; 30(6):1231-1238. PMC: 9321120. DOI: 10.1002/oby.23425. View

20.

Chao C, Wang J, Chien K . Both pre-frailty and frailty increase healthcare utilization and adverse health outcomes in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2018; 17(1):130. PMC: 6158921. DOI: 10.1186/s12933-018-0772-2. View